[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"First People's Hospital of Hangzhou\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":406},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,40,71,97,124,160,180,205,229,259,287,314,340,367,387],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100632383","single-channel-fibroid-morcellation-system-used-in-clinical-research-on-laparoscopic-myomectomy-100632383",false,"NCT07512973","Single-channel Fibroid Morcellation System Used in Clinical Research on Laparoscopic Myomectomy","Single-channel Fibroid Morcellation System Used in Clinical Research on Laparoscopic","Inclusion Criteria:\n\n1. Patients with uterine fibroids who meet the surgical criteria.\n2. Aged 18 and above but below 45, those who firmly request to retain the uterus.\n3. Patients planning to undergo laparoscopic removal of uterine fibroids.\n4. Those who understand the purpose, procedures, possible risks of this trial, voluntarily participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Patients whose overall condition cannot tolerate laparoscopic surgery.\n2. Patients who require surgeries other than laparoscopic fibroid removal surgery (excluding pelvic adhesion release, excision of mesosalpinx cysts less than 2cm, and excision\u002Felectrocoagulation of superficial intraperitoneal lesions).\n3. Considering the possibility of malignant transformation of uterine fibroids preoperatively.\n4. Preoperative diagnosis is unclear and needs to be differentiated from ovarian tumors.\n5. History of previous lower abdominal surgery or severe pelvic or abdominal adhesions.\n6. Presence of untreated infectious sexual diseases, including but not limited to vaginitis, cervicitis, and pelvic inflammatory disease.","FEMALE","18 Years","45 Years",{"count":20,"type":21},78,"ESTIMATED","INTERVENTIONAL",[24],"NA","This prospective, single-center, randomized, single-blind controlled trial aims to evaluate the efficacy and safety of a novel single-channel retrieval bag compared to a widely used dual-channel retrieval bag in laparoscopic myomectomy. A total of 78 patients aged 18 to 45 years with uterine fibroids (diameter ≥ 4 cm and requiring preservation of the uterus) will be randomly assigned to the experimental group and the control group in a 1:1 ratio. The experimental group will use the single-channel system (an upgraded high-transparency large-capacity retrieval bag + fragmentation device with a fibroid limiter), while the control group will utilize a standard dual-channel bag + fragmentation device with a fibroid limiter. The primary outcome measure will be the total surgical time. Secondary outcome measures will include the success rate of placement, intraoperative leakage rate, surgeon's learning curve, and intraoperative\u002Fpostoperative complications. Patients will be followed up at 3 months, 6 months, 12 months, and 24 months to assess recurrence and the risk of fibroid dissemination. Preliminary data (n = 22) indicate that the single-channel myomectomy fragmentation system significantly reduced total sampling time (15.4 minutes vs. 36.7 minutes, p = 0.005) while demonstrating comparable safety. This study utilizes the same electric fragmentation device for both the experimental and control groups, with the experimental group employing a further upgraded single-channel retrieval bag to verify the advantages of the novel single-channel retrieval bag in simplifying surgical procedures, improving efficiency, and providing a smoother learning curve, thereby offering evidence for its clinical promotion and patent conversion, particularly suitable for primary care hospitals.",[27],"Uterine Fibroids","NOT_YET_RECRUITING","2026-04-03",{"date":31,"type":32},"2026-04-06","ACTUAL",{"date":34,"type":21},"2026-05",{"date":36,"type":21},"2029-05",{"name":38,"class":39},"First People's Hospital of Hangzhou","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":70},"100631987","phase-2-exploratory-study-of-venetoclax-homoharringtonine-azacitidine-plus-g-csf-for-newly-diagnosed-aml-vhag-100631987","NCT07507825","Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)","A Prospective, Multicenter, Exploratory Study of Venetoclax, Homoharringtonine, and Azacitidine Combined With G-CSF in Elderly or Unfit Patients With Newly Diagnosed Acute Myeloid Leukemia","VHAG","Inclusion Criteria:\n\n* The patient has fully understood the study, voluntarily participated, and signed the informed consent form (ICF).\n* Newly diagnosed acute myeloid leukemia (AML) confirmed by bone marrow morphology, immunophenotyping, cytogenetics, and\u002For molecular biology testing, in accordance with the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (2022 edition).\n* No prior systemic therapy for AML (including induction, consolidation, or maintenance therapy).\n* Patients judged unfit for standard cytarabine plus anthracycline induction chemotherapy due to age or comorbidities.\n* Short-term use of hydroxyurea or low-dose cytarabine before enrollment to control hyperleukocytosis is permitted.\n* Age ≥ 75 years, or age 18-74 years with any of the following comorbidities:\n* ECOG performance status 2-3\n* History of congestive heart failure, left ventricular ejection fraction (LVEF) ≤ 50%, or chronic stable angina\n* Diffusing capacity of the lung for carbon monoxide (DLCO) ≤ 65% predicted, or forced expiratory volume in 1 second (FEV1) ≤ 65% predicted\n* Creatinine clearance 30-45 mL\u002Fmin (≥ 30 and \\\u003C 45)\n* Moderate hepatic impairment: total bilirubin \\> 1.5 × ULN and ≤ 3 × ULN\n* Other comorbidities deemed unfit for standard chemotherapy by the investigator\n* Estimated survival time ≥ 12 weeks.\n* For patients aged ≥ 75 years: ECOG performance status 0-2.\n* For patients aged 18-74 years: ECOG performance status 0-3.\n* Creatinine clearance ≥ 30 mL\u002Fmin (calculated by the Cockcroft-Gault formula).\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN).\n* Total bilirubin ≤ 1.5 × ULN; may be relaxed to ≤ 3 × ULN in patients with leukemic hepatic infiltration.\n* For patients \\\u003C 75 years old, total bilirubin ≤ 3 × ULN.\n\nExclusion Criteria:\n\n* Acute promyelocytic leukemia (APL).\n* History of prior myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, myelofibrosis, etc.\n* Prior receipt of hypomethylating agents, venetoclax (VEN), or systemic chemotherapy for myelodysplastic syndromes (MDS).\n* Prior receipt of any investigational drug or device therapy for MDS\u002FAML.\n* Concurrent participation in another clinical trial.\n* AML with central nervous system (CNS) involvement confirmed by imaging or cerebrospinal fluid examination.\n* Positive HIV antibody during the screening period.\n* Positive HBsAg or HCV antibody with a high-sensitivity viral load above the lower limit of detection within 3 months (excluding those who are cured or with persistent low-level replication).\n* Ingestion of grapefruit, grapefruit juice, Seville oranges, star fruit, or their products within 72 hours prior to the first dose.\n* Chronic respiratory failure requiring long-term oxygen therapy.\n* Presence of severe cardiac, hepatic, renal, endocrine, metabolic, immune, neurological, or psychiatric disorders.\n* History of hypersensitivity to the study drug (including azacitidine excipients).\n* Impaired drug absorption due to malabsorption syndrome, short bowel syndrome, or other conditions affecting oral drug absorption.\n* Active tuberculosis or other severe infections requiring intravenous anti-infective therapy for ≥7 days.\n* Presence of a second malignancy within 2 years prior to enrollment, excluding cured carcinoma in situ of the cervix or breast, completely resected basal cell carcinoma or localized squamous cell carcinoma of the skin, or localized malignancies cured by surgery and requiring no further follow-up.\n* The investigator judges that the patient is otherwise ineligible to participate in this study.","ALL",{"count":50,"type":21},61,[52],"PHASE2","This study is a single-arm, prospective, multi-center exploratory clinical trial. A total of 61 patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy will be enrolled. The Simon two-stage design will be adopted to control the type I and type II errors, with the minimum acceptable composite remission rate of 65% and a power of 80%.\n\nPrior to treatment, subjects will undergo screening within 28 days, including bone marrow aspiration, genetic testing, ECOG performance status assessment, and organ function evaluation. Data will be recorded in Excel and subject to unified quality control. During the treatment period, G-CSF (granulocyte colony-stimulating factor) will be administered subcutaneously as appropriate, and supportive care such as antiemetic and hydration therapy will be provided routinely.\n\nFor patients who achieve remission, individualized consolidation therapy will be given: those eligible for transplantation will undergo allogeneic hematopoietic stem cell transplantation; those who can tolerate moderate-intensity treatment will receive consolidation with medium-dose cytarabine first, followed by 4 cycles of VHAG regimen consolidation. Patients with FLT3 mutations will receive additional targeted therapy during consolidation.\n\nSafety assessment will be conducted in accordance with the NCI-CTCAE Version 5.0. For grade 4 hematological toxicity or severe non-hematological toxicity, the treatment dose will be adjusted or the treatment will be suspended. Severe adverse events will be reported in a timely manner, and all research-related data will be retained for at least 10 years in accordance with relevant regulations.",[55],"Acute Myeloid Leukemia (AML)",[57,58,59,60,61],"Acute myeloid leukemia (AML)","Venetoclax","Homoharringtonine","Azacitidine","Elderly\u002Funfit patients","2026-03-30",{"date":64,"type":32},"2026-04-02",{"date":66,"type":21},"2026-03-31",{"date":68,"type":21},"2029-03-31",{"name":38,"class":39},1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":4},"100623003","intradermal-acupuncture-for-assisting-ssri-dose-reduction-in-major-depressive-disorder-100623003","NCT07390981","Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder","Clinical Efficacy of Intradermal Acupuncture as an Adjunct to SSRI Dose Reduction or Discontinuation in Patients With Major Depressive Disorder and Its Mechanisms of Autonomic Nervous System Regulation","Inclusion Criteria:\n\n* Adults aged 18-60 years\n\nDiagnosis of major depressive disorder according to DSM-5\n\nCurrently receiving SSRI treatment and planning gradual dose reduction or discontinuation\n\nClear consciousness and ability to communicate normally\n\nWillingness to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Severe uncontrolled primary medical conditions\n\nDepression secondary to substances, medical illness, other psychiatric disorders (e.g., bipolar disorder, schizophrenia), or major bereavement\n\nActive suicidal ideation\n\nPregnancy or lactation\n\nCognitive impairment\n\nBleeding disorders or allergy to adhesive materials\n\nParticipation in another clinical trial within the past month","60 Years",{"count":80,"type":21},114,[24],"This randomized controlled trial aims to evaluate the clinical efficacy of intradermal acupuncture as an adjunctive intervention to assist selective serotonin reuptake inhibitor (SSRI) dose reduction or discontinuation in adult patients with major depressive disorder (MDD). Participants receiving SSRIs and planning gradual dose reduction or discontinuation will be randomly assigned to one of three groups: SSRI tapering alone, sham intradermal acupuncture plus SSRI tapering, or intradermal acupuncture plus SSRI tapering. Clinical outcomes and autonomic nervous system function will be assessed to determine the effectiveness and potential mechanisms of intradermal acupuncture in facilitating SSRI reduction and alleviating withdrawal-related symptoms.",[84],"Major Depressive Disorder",[86,87,88],"Intradermal Acupuncture","SSRIs","Heart Rate Variability","2026-03-23",{"date":91,"type":32},"2026-03-25",{"date":93,"type":21},"2026-03-01",{"date":95,"type":21},"2028-12-31",{"name":38,"class":39},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":16,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":70},"100565520","electroacupuncture-regulation-of-immune-cells-in-herpes-zoster-100565520","NCT06643247","Electroacupuncture Regulation of Immune Cells in Herpes Zoster","The Regulatory Mechanisms of Electroacupuncture Intervention on Immune Cells in Herpes Zoster","Inclusion Criteria for HZ:\n\n* Meets HZ diagnostic criteria;\n* Female, aged between 50 and 70 years;\n* Disease duration ≤7 days, with no prior antiviral, analgesic, or other treatments;\n* Herpetic lesions limited to the trunk, within 1 to 3 dermatomes;\n* Willing to participate in the trial and has signed the informed consent form.\n\nInclusion Criteria for HC:\n\n* No history of HZ or major cardiovascular, respiratory, digestive, urinary, hematologic, endocrine, or neurological diseases;\n* Age-matched female HC volunteers for the HZ group;\n* Clear consciousness and ability to communicate normally;\n* Fully understands the study protocol, demonstrates good compliance, and is willing to cooperate with the study;\n* Has signed a written informed consent form.\n\nExclusion Criteria:\n\n* Special types of herpes zoster, including ophthalmic, otic, visceral, meningeal herpes zoster, and zoster sine herpete;\n* Women who are planning to conceive, pregnant, or breastfeeding;\n* Patients with severe primary diseases of the circulatory, respiratory, or endocrine systems, or systemic failure;\n* Patients with bleeding tendencies;\n* Use of corticosteroids or immunosuppressants within the past month.",true,"50 Years","70 Years",{"count":108,"type":21},8,[24],"Herpes Zoster (HZ), caused by the Varicella-Zoster Virus (VZV), is a common infection characterized by localized pain and blistering, with higher incidence in females. HZ affects patients' physical health, mental well-being, and quality of life. The immune system is critical in HZ pathogenesis. Studies show acupuncture relieves pain, modulates immunity, and may lower postherpetic neuralgia (PHN) risk. However, evidence is limited on whether electroacupuncture (EA) alleviates HZ by modulating immune cells. Using mass cytometry (CyTOF), this study will analyze peripheral immune cell changes pre- and post-EA to explore its regulatory effects on HZ immunity. This study will recruit HZ patients and healthy controls (HC), dividing patients into medication-only and medication+EA groups to assess EA's potential immunomodulatory effects in HZ treatment.",[112,113,114],"Herpes Zoster","Electroacupuncture","Immune","RECRUITING","2026-02-01",{"date":118,"type":32},"2026-02-03",{"date":120,"type":32},"2024-11-11",{"date":122,"type":21},"2027-12-31",{"name":38,"class":39},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":22,"phases":135,"briefSummary":137,"conditions":138,"keywords":140,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":70},"100611581","phase-4-tegoprazan-plus-amoxicillin-bid-vs-tid-regimens-for-h-pylori-eradicationfrequency-adjusted-same-dose-therapy-for-h-pylori-100611581","NCT07242443","Tegoprazan Plus Amoxicillin BID vs TID Regimens for H. Pylori Eradication（Frequency Adjusted Same-dose Therapy for H. Pylori）","A Randomized Controlled Trial Comparing Tegoprazan 50 mg BID Combined With Amoxicillin 1 g TID Versus Tegoprazan 50 mg BID Combined With Amoxicillin 1.5 g BID for the Eradication of Helicobacter Pylori","FAST-HP","Inclusion Criteria:\n\n\\- 1.Adults aged 18 to 70 years. 2.Confirmed Helicobacter pylori infection by ¹³C-urea breath test, stool antigen test, or gastric biopsy.\n\n3.Able to provide written informed consent. 4.Willing and able to comply with all study procedures, including follow-up testing 4-8 weeks after treatment.\n\nExclusion Criteria:\n\n* 1.Known allergy or hypersensitivity to tegoprazan, amoxicillin, or any β-lactam antibiotics.\n\n  2.Use of antibiotics, proton pump inhibitors (PPIs), bismuth-containing agents, or potassium-competitive acid blockers within 4 weeks before screening.\n\n  3.Severe hepatic impairment (ALT or AST \\> 3 × upper limit of normal). 4.Severe renal impairment (estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n\n  5.Pregnant or breastfeeding women. 6.History of gastric surgery or conditions that may affect gastrointestinal absorption.\n\n  7.Participation in another clinical trial within the past 30 days. 8.Any condition that, in the investigator's judgment, would make the participant unsuitable for the study.","75 Years",{"count":134,"type":21},240,[136],"PHASE4","This study is designed to evaluate two different tegoprazan-based dual therapy regimens for the treatment of Helicobacter pylori (H. pylori) infection. All participants will receive tegoprazan 50 mg twice daily for 14 days, combined with one of two amoxicillin dosing schedules that contain the same total daily dose of 3 grams of amoxicillin.\n\nOne group will receive amoxicillin 1 gram three times daily (TID), which is the standard regimen. The other group will receive amoxicillin 1.5 grams twice daily (BID), an alternative schedule that may improve convenience and treatment adherence while maintaining the same total daily antibiotic amount.\n\nA total of 240 adults with confirmed H. pylori infection will be randomly assigned to one of the two treatment groups. The main goal of the study is to compare the H. pylori eradication rates between the two regimens. Eradication will be assessed 4 to 8 weeks after completing therapy using a ¹³C-urea breath test. Safety, tolerability, and medication adherence will also be monitored.",[139],"HELICOBACTER PYLORI INFECTIONS",[141,142,143,144,145,146,147,148,149,150,151],"Helicobacter pylori","H. pylori","Amoxicillin","Tegoprazan","Dual Therapy","BID Dosing","TID Dosing","Fixed-Dose Regimen","P-CAB","Frequency Comparison","Antibiotic Regimen Optimization","2025-11-17",{"date":154,"type":32},"2025-11-21",{"date":156,"type":21},"2025-11-20",{"date":158,"type":21},"2026-12-31",{"name":38,"class":39},{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":165,"acronym":166,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":106,"enrollmentInfo":168,"targetDuration":4,"studyType":22,"phases":169,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":174,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":70},"100611582","phase-2-head-to-head-study-of-tegoprazan-50-mg-bid-plus-amoxicillin-1-g-tid-vs-vonoprazan-20-mg-bid-plus-amoxicillin-1-g-tid-for-h-pylori-eradication-100611582","NCT07242456","Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication","Head-to-head Comparison of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID Versus Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for Helicobacter Pylori Eradication: A Randomized, Open-label, Parallel-group Study","TV-HP","Inclusion Criteria:\n\n* 1\\. Adults aged 18 to 70 years. 2. Confirmed Helicobacter pylori infection based on at least one positive test (13C-urea breath test, rapid urease test, histology, or stool antigen test). 3. Able and willing to provide written informed consent. 4. Able to comply with study procedures and visits. 5. For females of childbearing potential: agreement to use effective contraception during the study period.\n\nExclusion Criteria:\n\n* 1\\. Previous Helicobacter pylori eradication therapy within the past 12 months. 2. Use of antibiotics, bismuth compounds, or other medications with anti-H. pylori activity within 4 weeks before baseline testing. 3. Use of proton pump inhibitors, P-CABs, or H2-receptor antagonists within 2 weeks before baseline testing. 4. Known allergy or intolerance to tegoprazan, vonoprazan, amoxicillin, or any beta-lactam antibiotic. 5. Known severe hepatic impairment (e.g., Child-Pugh C) or severe renal impairment (e.g., eGFR \\\u003C 30 mL\u002Fmin\u002F1.73 m²). 6. History of gastric surgery (except minor endoscopic procedures that do not affect gastric anatomy).\n\n  7\\. Active gastrointestinal bleeding or suspected gastric malignancy. 8. Pregnant or breastfeeding women. 9. Participation in another interventional clinical trial within the past 30 days.\n\n  10\\. Any medical or psychiatric condition that, in the investigator's judgment, could interfere with study participation or pose unacceptable risk.",{"count":134,"type":21},[52,170],"PHASE3","This study is a randomized, open-label, parallel-group clinical trial designed to compare two 14-day dual therapies for the eradication of Helicobacter pylori (H. pylori) infection. Participants will be randomly assigned to receive either tegoprazan 50 mg twice daily plus amoxicillin 1 g three times daily, or vonoprazan 20 mg twice daily plus amoxicillin 1 g three times daily.\n\nThe primary purpose of this study is to evaluate whether the tegoprazan-based regimen is non-inferior to the vonoprazan-based regimen in terms of H. pylori eradication rates. Eradication will be assessed 4 to 8 weeks after completing therapy using a \\^13C-urea breath test. Secondary objectives include assessing treatment-related adverse events, tolerability, and medication adherence.\n\nThis study involves adult participants with confirmed H. pylori infection. All study medications are orally administered, and both regimens use drugs with well-established safety profiles. The study is investigator-initiated and conducted at Hangzhou First People's Hospital.",[173],"Helicobacter Pylori Infection",{"date":154,"type":32},{"date":176,"type":32},"2025-02-17",{"date":178,"type":21},"2026-01-31",{"name":38,"class":39},{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":186,"enrollmentInfo":187,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":190,"conditions":191,"keywords":193,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":70},"100608878","multi-omics-molecular-characteristics-and-immunophenotyping-of-lung-signet-ring-cell-carcinoma-100608878","NCT07207278","Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma","Inclusion Criteria:\n\n1.Histologically confirmed, previously untreated LSRCC; 2. Adequate FFPE tumor tissue and paired adjacent non-tumor tissue available; 3. Expected survival ≥ 12 weeks; 4. Patients (or their legal guardians) willing and able to provide written informed consent; 5.Availability of complete pathology and imaging data.\n\nExclusion Criteria:\n\n1\\. Prior systemic anticancer therapy; 2. Secondary LSRCC (i.e., metastatic signet ring cell carcinoma originating from a non-lung primary site); 3. Concurrent other malignancies; 4. Incomplete pathology results, missing imaging data, or unreliable follow-up information; 5. Pregnancy or lactation","85 Years",{"count":188,"type":21},39,"OBSERVATIONAL","This study aims to reveal the molecular characteristics and immune microenvironmental profile of signet ring cell carcinoma of the lung (LSRCC) in the Chinese population through integrated multi-omics analyses. The project plans to enroll formalin-fixed paraffin-embedded (FFPE) tissue samples and paired adjacent tissues from 39 patients with previously untreated LSRCC to establish a Chinese LSRCC molecular database. Whole-exome sequencing (WES) will be used to analyze gene mutations, such as single nucleotide variants (SNVs), copy number variants (CNVs), and fusion events. RNA-seq will be used to screen for differentially expressed genes (DEGs) and perform immunophenotyping, while multiplex immunohistochemistry will be employed to quantify the tumor immune microenvironment (TIME). The successful implementation of this project is expected to identify novel molecular biomarkers specific to the Chinese LSRCC population, enhance understanding of the unique immune phenotypes within this group, and-combined with clinical follow-up-establish correlations between molecular\u002Fimmune signatures and therapeutic efficacy assessments, thereby providing evidence-based medical support for subsequent personalized precision diagnosis and treatment of LSRCC in this population.",[192],"Signet Ring Cell Carcinoma of the Lung",[194,195,196],"LSRCC","Multi-omics analysis","Immune subtyping","2025-09-28",{"date":199,"type":32},"2025-10-03",{"date":201,"type":32},"2025-09-01",{"date":203,"type":21},"2027-08-31",{"name":38,"class":39},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":212,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":70},"100428626","the-safety-and-efficiency-of-endovascular-treatment-of-acute-or-subacute-thromboembolic-occlusions-of-lower-extremity-100428626","NCT04861506","The Safety and Efficiency of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Physician-initiated, Prospective, Multi-center, Observational Study: The Safety and Efficiency Result of Endovascular Treatment of Acute or Subacute Thromboembolic Occlusions of Lower Extremity.","Inclusion criteria\n\n1. Patients aged 18 years or older.\n2. Diagnosis of acute or subacute limb ischemia classified as Rutherford classification stage I to IIb.\n3. Rutherford classification ranging from 3 to 5.\n4. Successful guidewire passage through the lesion of the femoropopliteal artery lesion, followed by further endovascular treatment. There are no restrictions will be implemented on the methods used for guidewire passage through the target lesion. The presence of thrombus must be confirmed via angiography and\u002For DSA and must be associated with occlusions of the lower extremity or ISR.\n5. Mechanical thrombectomy device (MTD) and\u002For pharmacomechanical thrombectomy (PMT) and\u002For percutaneous aspiration thrombectomy(PAT) and\u002For CDT (catheter-directed thrombolysis) performed for thrombus removal.\n6. The lower extremity artery must have a healthy runoff of at least 10 cm above the ankle with at least one healthy dorsalis pedis artery, medial plantar artery, or lateral plantar artery connecting to the digital artery below the ankle.\n7. Informed consent signed by patients.\n\nExclusion criteria\n\n1. Acute or subacute limb ischemia patients with Rutherford classification stage III.\n2. Patients diagnosed with thromboangiitis obliterans.\n3. Patients requring open surgery or hybrid operation after contrast radiography.\n4. Patients with a history of stroke, cerebral hemorrhage, gastrointestinal bleeding, myocardial infarction, or similar conditions in the past 3 months.\n5. Patients with known allergies to heparin, low molecular weight heparin, or contrast agents.\n6. Patients at high risk for bleeding.\n7. Pregnant or lactating women.\n8. Patients with other conditions that may complicate study participation or significantly reduce life expectancy (\\\u003C 2 years), such as tumors, severe liver disease, and cardiac insufficiency.\n9. Patients enrolled in other clinical studies within the past 3 months.\n10. Patients unwilling or refusing to sign the informed consent form.\n\n    \\-",{"count":213,"type":21},400,"Based on the development of new tools, including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools, More and more acute or subacute thromboembolic occlusions of lower extremity included stage IIb were treated with endovascular procedures. Most guidelines suggests only stage I and stage IIa lesions are suitable for endovascular treatments. Therefore, a well-designed real-world study that track the safety and clinical relevant outcomes, are required to determine the optimal therapies for patients with acute or subacute thromboembolic occlusions of lower extremity.",[216,217,218,219,220],"Thromboembolic Disease","Lower Extremity Problem","Endovascular Treatment","Safety Issues","Efficacy, Self","2025-09-12",{"date":223,"type":32},"2025-09-15",{"date":225,"type":32},"2021-04-01",{"date":227,"type":21},"2025-12-31",{"name":38,"class":39},{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":16,"minAge":236,"maxAge":237,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":245,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":251,"lastUpdatePostDateStruct":252,"startDateStruct":254,"completionDateStruct":256,"leadSponsor":258,"locationsCount":70},"100504852","phase-4-study-of-tenofovir-alafenamide-in-hbv-infected-pregnant-women-100504852","NCT05853718","Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women","Study to Evaluate the Pharmacokinetic, Safety, and Efficacy of TAF in HBV-Infected Pregnant Women","Inclusion Criteria:\n\n* Age of 20-40 years; Positive for hepatitis B surface antigen (HBsAg) and hepatitis B virus e antigen (HBeAg); HBV DNA level \\>200 000 IU\u002FmL during the 24th-32nd week of pregnancy; Willing to take TAF for mother-to-child blockade; Both husband and wife are willingly sign an informed consent.\n\nExclusion Criteria:\n\n* Co-infected with hepatitis C or HIV, or other chronic diseases; History of spontaneous abortion or congenital malformation; Decompensated cirrhosis and liver cancer; History of kidney injury, CCr \\\u003C50ml\u002Fmin and urine protein test positive (\\>300mg\u002FL); Fetal malformations detected by B-ultrasound during pregnancy; ALT \\> 2×upper limit of normal (ULN); TBIL ≥ 1×ULN; Albumin (ALB) \\\u003C 25 g\u002FL.","20 Years","40 Years",{"count":239,"type":21},50,[136],"The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.",[243,244],"Chronic Hepatitis b","Tenofovir Alafenamide Fumarate",[246,247,248,249,250],"pharmacokinetics","CHB","TAF","pregnancy","mother-to-child transmission","2025-08-31",{"date":253,"type":32},"2025-09-08",{"date":255,"type":32},"2021-05-06",{"date":257,"type":21},"2025-12-30",{"name":38,"class":39},{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":266,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":269,"briefSummary":270,"conditions":271,"keywords":274,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":70},"100574916","the-study-evaluating-the-improvement-of-nutritional-status-and-frailty-with-silkworm-pupa-powder-among-patients-with-motor-neuron-disease-100574916","NCT06765499","The Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Among Patients With Motor Neuron Disease","A Prospective, Double-blind, Randomized Controlled Study Evaluating the Improvement of Nutritional Status and Frailty With Silkworm Pupa Powder Compared With Placebo Among Motor Neuron Disease","Inclusion Criteria:\n\n* Voluntarily participate in the clinical study, fully understand and be informed about the study, and sign the Informed Consent Form (ICF); willing to follow and capable of completing all trial procedures.\n* Gender is not limited, age at the time of signing ICF: ≥18 years old, ≤80 years old; if the ALS patient is at least 18 years old, then the weight must be over 40 kilograms.\n* Diagnosis conforms to the confirmed and probable ALS in the ALS2020 diagnostic criteria (Gold Coast Criteria).\n* Clinical, neurophysiological, or pathological examination confirms evidence of lower motor neuron involvement.\n* Frailty Phenotype scale (FP) ≥1.\n* Exclude other diseases.\n* Agree to provide peripheral blood, fecal, and urine samples for biomarker analysis during the study period.\n\nExclusion Criteria:\n\n* Patients with other neurological diseases similar to ALS symptoms or affecting drug efficacy evaluation, such as cervical spondylosis, lumbar disease, dementia, etc.\n* Patients with other autoimmune diseases, such as Multiple Sclerosis (MS), Polymyositis, Myasthenia Gravis, Guillain-Barré Syndrome, Ankylosing Spondylitis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Vitiligo, etc.\n* Severe renal insufficiency: Creatinine clearance \\\u003C 30 mL\u002Fmin (Cockcroft-Gault formula), or other known severe renal insufficiency diseases.\n* Severe liver damage: ALT, AST \\> 3 times the upper limit of normal, or other known liver diseases such as acute and chronic active hepatitis, cirrhosis, etc.\n* Patients with severe pulmonary function insufficiency such as Chronic Obstructive Pulmonary Disease (COPD), pulmonary fibrosis, etc.\n* During the screening period, patients with acute myocardial infarction or interventional treatment within the last 6 months, heart failure patients (classified as NYHA class III-IV patients).\n* Patients with other severe primary diseases of the nervous system, heart, lungs, hematopoietic system, or endocrine system, and mental illness patients.\n* Those suspected or confirmed to have a history of alcohol or drug abuse.\n* Expected survival ≤ 3 months.\n* Pregnant or breastfeeding women, subjects of reproductive age (including male subjects who have had heterosexual intercourse and their female partners with childbearing potential) who plan to become pregnant or are unwilling to take effective contraceptive measures from the start of screening to 3 months after discontinuing medication.\n* Those who are allergic to known ingredients of the trial products; or have a history of drug allergies or severe allergic diseases (anaphylactic shock, etc.).\n* During the study, individuals assessed by researchers as potential drug abusers who may affect the efficacy of therapeutic drugs.\n* Presence of other severe physical or mental diseases or abnormal laboratory tests that may increase the risk of participating in the study and patients deemed unsuitable for participation by the researcher.\n* Patients with malignant tumors.","80 Years",{"count":268,"type":21},100,[24],"Motor Neuron Disease (MND) is the result of dysfunction of the upper motor neurons in the precentral gyrus of the frontal lobe or the lower motor neurons in the ventral horn of the spinal cord. Amyotrophic lateral sclerosis (ALS) is the most common, disabling, and fatal motor neuron disease in adults. Sarcopenia is a syndrome characterized by progressive loss of skeletal muscle mass, accompanied by a reduction in muscle strength and (or) function, and it is an important feature of MND. Aging is an objective and inevitable process that involves the gradual degeneration and loss of physiological functions in various tissues, organs, and cells. With the continuous accumulation of various injuries, the body eventually exhibits signs of frailty such as fatigue, reduced muscle strength, and weight loss. Data from adult ALS patients indicate that 58% of patients are at risk of frailty. Silkworm pupa contains high-quality animal protein and has a wide range of activities in antioxidant, antitumor, antibacterial, and immune enhancement, making it highly nutritious and medicinally valuable. Silkworm pupa extracts can enhance grip strength in older adults with relatively low skeletal muscle mass. As a natural food ingredient with high safety, the value of silkworm pupa in ALS patients lacks corresponding research, which limits its further application in clinical practice. This study aims to select ALS patients as the research subjects and use a randomized, controlled, double-blind prospective study design to evaluate the effectiveness of silkworm pupa tablets in improving sarcopenia, frailty, and quality of life in ALS patients. The study strives to improve the frailty condition of ALS patients and enhance their quality of life by supplementing nutrition, thereby providing new strategies for comprehensive intervention and management of ALS patients.",[272,273],"Motor Neuron Disease (MND)","Amyotrophic Lateral Sclerosis (ALS)",[275,276,277,278],"Amyotrophic Lateral Sclerosis","Motor Neuron Disease","Frailty","Nutritional Status","2025-04-30",{"date":281,"type":32},"2025-05-04",{"date":283,"type":32},"2025-03-04",{"date":285,"type":21},"2026-12-30",{"name":38,"class":39},{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":4,"eligibilityCriteria":293,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":22,"phases":296,"briefSummary":297,"conditions":298,"keywords":300,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":70},"100571288","phase-2-chemotherapy-plus-immunotherapy-combined-with-sbrt-as-neoadjuvant-therapy-for-patients-with-resectable-nsclc-100571288","NCT06718309","Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC","A Prospective Cohort Study of Chemotherapy Plus Immunotherapy Combined With Stereotactic Body Radiotherapy as Neoadjuvant Therapy for Patients With Resectable Non-small Cell Lung Cancer","Inclusion Criteria:\n\n1. Histologically or pathologically confirmed, newly diagnosed non-small cell lung cancer patients;\n2. Age ≥18 years;\n3. (Eastern Cooperative Oncology Group, ECOG) (Performance Status, PS) score 0-1;\n4. According to the 8th-9th edition of (American Joint Committee on Cancer, AJCC) (stage II-IIIA, for stage IIIB included T3-4N2, T4 only included tumor \\> 7cm);\n5. Puncture or biopsy samples were tested EGFR\u002FALK negative;\n6. Surgically or potentially resectable after discussion by multidisciplinary team (MDT);\n7. Who has not received systemic antitumor therapy and has not received chest radiotherapy;\n8. Evaluable lesions in the lung or mediastinum;\n9. The organ function level should meet the following criteria one week before enrollment: 1) Bone marrow function: hemoglobin ≥80g\u002FL, white blood cell count ≥4.0\\*10\\^9\u002FL or neutrophil count ≥1.5\\*10\\^9\u002FL, platelet count ≥100\\*10\\^9\u002FL; 2) Liver: total serum bilirubin level ≤1.5 times the normal upper limit, when serum total bilirubin level \\> 1.5 times the normal upper limit, direct bilirubin level ≤ normal upper limit, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 times the normal upper limit; 3) Kidney: blood creatinine level \\\u003C 1.5 times the normal upper limit or creatinine clearance ≥50ml\u002Fmin, urea nitrogen ≤200mg\u002FL; Serum albumin ≥30g\u002FL;\n10. Male\u002Ffemale of childbearing age agrees to use contraception during the trial period (surgical ligation or oral contraceptives\u002FIUDs + condom contraception);\n11. Sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with severe dysfunctions of the heart, lungs and other organs who are not suitable for surgery;\n2. Patients with severe autoimmune diseases: active inflammatory bowel disease (including Crohn's disease, ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (such as Wegener's granuloma), etc;\n3. Other malignancies within 5 years (excluding non-melanoma skin cancer and cervical cancer);\n4. Patient with active infection, heart failure, heart attack, unstable angina pectoris or unstable arrhythmia within the last 6 months;\n5. Congenital or acquired immunodeficiency disorders include human immunodeficiency virus (HIV) or a history of organ transplantation or allogeneic stem cell transplantation;\n6. Patients treated with other immunological agents, chemotherapy agents, other drugs in clinical trials and long-term cortisol therapy were excluded;\n7. Patients who are allergic or contraindicated to PD-1 inhibitors.",{"count":295,"type":21},40,[52],"In this study, patients with EGFR\u002FALK wild-type, resectable locally advanced NSCLC are expected to receive 1 cycle of chemoimmunotherapy as neoadjuvant therapy, followed by SBRT to the primary lung lesion, and chemoimmunotherapy for 2 cycles. Surgical treatment will be given within 4-6 weeks after the last cycle of chemoimmunotherapy, then immunotherapy maintenance for 1 year.",[299],"Non-Small Cell Lung Cancer",[301,302,303,304,305],"NSCLC","locally advanced","resectable","SBRT","immunotherapy","2024-12-01",{"date":308,"type":32},"2024-12-05",{"date":310,"type":32},"2024-04-24",{"date":312,"type":21},"2029-04-30",{"name":38,"class":39},{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":4,"eligibilityCriteria":320,"healthyVolunteers":11,"sex":48,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":189,"phases":4,"briefSummary":325,"conditions":326,"keywords":328,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":339,"locationsCount":70},"100570182","study-on-clostridium-difficile-infection-in-infants-100570182","NCT06703918","Study on Clostridium Difficile Infection in Infants","A Retrospective Cohort Study on the Epidemiological Characteristics and Biomarkers of Clostridium Difficile Infection in Infants","Inclusion Criteria:\n\n* Infants ( aged 0-2 years). Medical records and patient questionnaires available with confirmed Clostridium difficile infection (for case group) or without infection (for control group).\n\nExclusion Criteria:\n\n* Infants beyond the age of 2 years at the time of diagnosis. Incomplete medical records or missing essential information related to infection status, feeding methods, or antibiotic exposure.Patients with other severe gastrointestinal conditions that may confound results.","0 Months","24 Months",{"count":324,"type":21},150,"This study aims to investigate the epidemiological characteristics and biomarkers of Clostridium difficile infection in infants . By analyzing historical medical data and patient questionnaires, this retrospective cohort study will identify potential high-risk factors and establish baseline biomarkers to improve diagnosis and treatment for affected patients.",[327],"Clostridium Difficile Infection",[329,330,331,332],"Clostridium difficile","Infants","Epidemiology","Biomarkers","2024-11-21",{"date":335,"type":32},"2024-11-25",{"date":337,"type":32},"2024-07-01",{"date":285,"type":21},{"name":38,"class":39},{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":347,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":355,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":4},"100552892","hysteroscopic-suture-fixation-of-mirena-in-the-treatment-of-adenomyosis-100552892","NCT06478992","Hysteroscopic Suture Fixation of Mirena in the Treatment of Adenomyosis","A Multicenter Randomized Controlled Trial of Hysteroscopic Suture Fixation of Mirena in the Treatment of Adenomyosis","Inclusion Criteria:\n\n* Pain due to adenomyosis (lower abdominal pain and low back pain) visual analogue scale (VAS) ≥40mm or menstrual volume score (PBAC) ≥100;\n\n  * Adenomyosis was confirmed by ultrasound or magnetic resonance imaging (MRI);\n\n    * The uterine volume measured by transvaginal gynecological three-dimensional ultrasound was more than 150cm3 and less than 280cm3 (the volume was about 280cm3 at 10 weeks of pregnancy); ④ A strong desire to preserve the uterus; ⑤ No fertility requirements within nearly one year;\n\n      * Premenopausal women aged ≥18 years old; ⑦ Willing and able to abide by the study protocol, and have the ability to clearly judge the amount of menstruation and the degree of pain.\n\nExclusion Criteria:\n\n* Presence of contraindications to Mirena (known or suspected pregnancy, current pelvic inflammatory disease or recurrent pelvic inflammatory disease, lower genital tract infection, postpartum endometritis, infectious abortion within the past 3 months, cervicitis, cervical dysplasia, uterine or cervical malignant lesions, progestin-dependent tumors, abnormal uterine bleeding of unknown cause, congenital or acquired uterine abnormalities, these include fibroids that deform the cervix, conditions that increase susceptibility to infections, acute liver diseases or tumours, allergy to active ingredients or excipient);\n\n  * Malignant tumors (including reproductive system and other systems);\n\n    * Acute stage of heart, liver and kidney failure or other patients who cannot tolerate operation;\n\n      * The history of Mirena displacement or expulsion;\n\n        * Ultrasound showed the presence of ovarian chocolate cyst; ⑥ The presence of deep endometrial nodules by gynecological examination;\n\n          * The presence of intramural or subserous myoma ≥3cm or any size of uterine submucosal myoma (type 0, 1, 2); ⑧ Patients who are unwilling to participate in the study or who were considered by the investigators to be unsuitable for the study.","55 Years",{"count":349,"type":21},144,[24],"The purpose of this study was to evaluate the efficacy and safety of hysteroscopic Mirena fixation in patients with adenomyosis with enlarged uterus, compared with simple Mirena placement under hysteroscopy. Whether the curative effect is not inferior to and reduces the incidence of Mirena expulsion.",[353,354],"Adenomyosis","Hysteroscopy",[356,357,358,353],"Suture fixation","Expulsion","Mirena","2024-06-23",{"date":361,"type":32},"2024-06-27",{"date":363,"type":21},"2024-06-30",{"date":365,"type":21},"2026-06-30",{"name":38,"class":39},{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":373,"targetDuration":4,"studyType":22,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":70},"100550095","clinical-research-on-the-application-of-single-channel-uterine-fibroid-morcellation-system-in-laparoscopic-myomectomy-100550095","NCT06442605","Clinical Research on the Application of Single-channel Uterine Fibroid Morcellation System in Laparoscopic Myomectomy","Inclusion Criteria:\n\nPatients with uterine fibroids who meet the surgical indications. Patients aged 18 and above but below 45, who strongly request to preserve the uterus.\n\nPatients planning to undergo laparoscopic myomectomy. Those who understand the purpose, procedures, potential risks of this trial, voluntarily participate in this study, and sign the informed consent form.\n\nExclusion Criteria:\n\nPatients who cannot tolerate laparoscopic surgery due to their overall physical condition.\n\nPatients with multiple fibroids have at least 4 fibroids, with the largest diameter of a single fibroid being equal to or greater than 10cm.\n\nPatients who require surgical procedures other than laparoscopic myomectomy (excluding pelvic adhesion lysis, resection of mesosalpingeal cysts measuring less than 2cm, and superficial intraperitoneal lesions resection\u002Felectrocoagulation).\n\nPreoperatively considering the possibility of uterine fibroid malignancy. Patients with preoperative unclear diagnosis, requiring differentiation from ovarian tumors.\n\nPreviously undergone lower abdominal or pelvic intraperitoneal surgery, or patients with severe pelvic or abdominal adhesions.\n\nPresence of untreated infectious sexual diseases, including but not limited to vaginitis, cervical inflammatory diseases, and pelvic inflammatory diseases.\n\nPatients who cannot understand the research protocol, cannot cooperate with the research and follow-up, and any other patients that researchers deem unsuitable for participation in this study.",{"count":374,"type":21},22,[24],"Research Purpose The purpose of this study is to explore whether the application of a single-channel uterine fibroid morcellation system compared to a multi-channel specimen retrieval bag during laparoscopic myomectomy can shorten the operative time and improve the efficiency of fibroid removal.\n\nResearch Design This study is a single-center, randomized, single-blind, 1:1 controlled trial.\n\nIntervention Measures Study participants were randomly assigned in a 1:1 ratio into two groups.\n\nExperimental group: Conventional laparoscopic myomectomy with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids.\n\nControl group: Conventional laparoscopic myomectomy with the use of a multi-channel specimen retrieval bag and a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.\n\nObservation Indicators Primary observation indicator: Time required for fibroid fragmentation and retrieval (from the placement of the single-channel uterine fibroid morcellation system or the multi-channel specimen retrieval bag to complete removal from the abdominal cavity).\n\nSecondary observation indicators: Success rate of placement, intraoperative damage and leakage rate, gynecological surgeon satisfaction with the surgery, total weight of retrieved uterine fibroid fragments.",[378],"Leiomyoma, Uterine","2024-06-03",{"date":381,"type":32},"2024-06-04",{"date":383,"type":21},"2024-06-20",{"date":385,"type":21},"2027-06-19",{"name":38,"class":39},{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":48,"minAge":17,"maxAge":4,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":395,"briefSummary":396,"conditions":397,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":70},"100490537","treatment-of-advance-gastric-cancer-with-disulfiram-100490537","NCT05667415","Treatment of Advance Gastric Cancer With Disulfiram","Clinical Study of Disulfiram Combined With Cisplatin in the Treatment of Advanced Gastric Cancer","1. Inclusion criteria: ① Age ≥18 years old; ② Gastric cancer is confirmed through gastroscopy biopsy; ③ The patient meets the relevant diagnostic criteria in People's Republic of China (PRC) Health Industry Standards: Diagnostic Criteria for Gastric Cancer, and has reached the level of stage III and IV futures, and the patient refuses to receive surgical treatment; ④ Estimated survival time \\> 3 months; ⑤ Without any chemotherapy treatment or more than one month from the end of the last chemotherapy course; ⑥Karnofsky functional status score ≥ 60;\n2. Exclusion criteria: ① patients who had allergic reaction to therapeutic drugs; ② patients with other types of cancer; ③ Patients with severe diseases of heart, liver, kidney, etc.; (4) gastrointestinal dysfunction or unable to oral medication.\n3. Shedding\u002Feliminating criteria: exiting in the midway; Lost to follow-up during the follow-up period; Treatment was not continued according to the treatment protocol.",{"count":295,"type":21},[24],"Chemotherapy is generally needed for advanced gastric cancer, and cisplatin is the main chemotherapy drug. However, there are many adverse reactions, including bone marrow suppression, gastrointestinal reactions, renal toxicity and neurotoxicity. These adverse reactions can affect the comfort and compliance of patients during treatment. At present, it is necessary to reduce adverse reactions of cisplatin and increase the chemotherapy sensitivity of gastric cancer to cisplatin. Recent studies have found that disulfiram has a potential anti-tumor effect. The disulfiram has shown significant in vivo and in vitro anti-tumor activity in preclinical studies, and has become a potential candidate drug for tumor treatment as an adjuvant in various clinical trials. In this clinical study, cisplatin combined with disulfiram is mainly used to treat advanced gastric cancer.",[398],"Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram","2022-12-26",{"date":401,"type":32},"2022-12-28",{"date":403,"type":21},"2023-06-01",{"date":365,"type":21},{"name":38,"class":39},""]